Targeting Purine Metabolism With 6‐Mercaptopurine Overcomes Solute Carrier Family 7 Member 2 Deficiency‐Induced Cisplatin Resistance in Tongue Squamous Cell Carcinoma
Oral Diseases · 15.07.2026
DOI: 10.1111/odi.70401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 15.07.2026. Verfasst von Yu-Lu Mao und 5 weiteren Autor:innen. Beteiligte Einrichtung: GuiZhou University Medical College, Guiyang, Guizhou Province, China. Hauptthemen laut MEDLINE: Cisplatin, Tongue Neoplasms, Drug Resistance, Neoplasm, Mercaptopurine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: the Guiyang Stomatological Hospital High-level Talents Program, Health Commission of Guizhou Province.
Abstract (Originalsprache)
Background
Cisplatin resistance remains a major clinical obstacle in the treatment of tongue squamous cell carcinoma (TSCC). Solute carrier family 7 member 2 (SLC7A2) is a key cationic amino acid transporter, yet its functional significance in TSCC drug resistance has not been explored.
Methods
We established cisplatin‐resistant TSCC cell lines and performed integrated proteomics and metabolomics. SLC7A2 function was assessed via gain‐of‐function and loss‐of‐function assays combined with CCK‐8, Transwell, wound healing, flow cytometry, Western blot, and RT‐qPCR.
Results
SLC7A2 was markedly downregulated in both TSCC tissues and cisplatin‐resistant cells. Multi‐omics analysis revealed significant perturbations in purine metabolism, identifying 6‐mercaptopurine (6‐MP) as a critical metabolite. SLC7A2 overexpression or combined Cis+6‐MP treatment synergistically suppressed proliferation, migration, and invasion while promoting apoptosis. Mechanistically, SLC7A2 expression correlated with p53 signaling activity: SLC7A2 knockdown increased MDM2 expression and induced cisplatin resistance, while SLC7A2 overexpression or Cis+6‐MP treatment reversed these effects. Pharmacological inhibition of p53 with PFT‐α sensitized cells to cisplatin, whereas p53 activation with Nutlin‐3a partially reversed resistance in a p53‐dependent manner.
Conclusion
This study identifies SLC7A2 as a regulator of cisplatin response in TSCC, acting through the p53 signaling network. It also highlights 6‐MP as a sensitizer, offering a combination strategy to overcome chemoresistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GuiZhou University Medical College, Guiyang, Guizhou Province, China.
- Department of Oral and Maxillofacial Surgery, Guiyang Stomatological Hospital, Guiyang, China.
- College of Stomatology, Guizhou Medical University, Guiyang, China.
- Department of Clinical Laboratory, Guiyang Stomatological Hospital, Guiyang, China.
ORCID-Profile: Yu-Lu Mao, Yu-Long Ouyang
Förderung
- the Guiyang Stomatological Hospital High-level Talents Program
- Health Commission of Guizhou Province
Zitieren
APA
Mao, Y. L., Mao, B. Y., Ouyang, Y. L., Zhang, Y., Cheng, P., & Feng, H. C. (2026). Targeting Purine Metabolism With 6‐Mercaptopurine Overcomes Solute Carrier Family 7 Member 2 Deficiency‐Induced Cisplatin Resistance in Tongue Squamous Cell Carcinoma. Oral Diseases. https://doi.org/10.1111/odi.70401
Vancouver
Mao YL, Mao BY, Ouyang YL, Zhang Y, Cheng P, Feng HC. Targeting Purine Metabolism With 6‐Mercaptopurine Overcomes Solute Carrier Family 7 Member 2 Deficiency‐Induced Cisplatin Resistance in Tongue Squamous Cell Carcinoma. Oral Diseases. 2026. doi:10.1111/odi.70401
BibTeX
@article{Mao2026,
author = {Mao, Yu-Lu and Mao, Ben-Yuan and Ouyang, Yu-Long and Zhang, Yi and Cheng, Ping and Feng, Hong-Chao},
title = {Targeting Purine Metabolism With 6‐Mercaptopurine Overcomes Solute Carrier Family 7 Member 2 Deficiency‐Induced Cisplatin Resistance in Tongue Squamous Cell Carcinoma},
journal = {Oral Diseases},
year = {2026},
doi = {10.1111/odi.70401}
}
EUVIMED